We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA (CATARA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01204138
Recruitment Status : Withdrawn (decision of sponsor to withdraw before initiation; 0 patients enrolled)
First Posted : September 17, 2010
Last Update Posted : February 5, 2016
Information provided by (Responsible Party):

September 10, 2010
September 17, 2010
February 5, 2016
September 2010
August 2011   (Final data collection date for primary outcome measure)
20% improvement based on ACR responder criteria [ Time Frame: 12 weeks ]
Same as current
Complete list of historical versions of study NCT01204138 on ClinicalTrials.gov Archive Site
ACR 50/70 and DAS [ Time Frame: 12 weeks ]
Same as current
Not Provided
Not Provided
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
A Phase II, single institution, double blind, randomized, placebo controlled, cross-over study exploring the safety and efficacy apremilast in patients with active RA with concomitant use of TNF inhibition. Following a screening period, patients with active disease on stable TNF inhibition will be randomized to receive either apremilast or placebo for a period of 12 weeks. At the end of 12 weeks patients will be assessed for efficacy using the ACR responder index looking for a 20% improvement, then all patients initially randomized and treated in a blinded fashion with apremilast will be crossed over to placebo while those patients initially randomized and treated with placebo will be crossed over to apremilast. Patients will be followed for an additional 12 weeks on treatment to assess both safety and efficacy of this combination treatment. Following 24 weeks of active treatment or early termination, patients will undergo a 28 day safety visit.

The primary objective of this study is to evaluate the efficacy of apremilast when used in combination with a background DMARD and TNF inhibition in patients with active RA using the ACR responder index looking for a 20% improvement.

To evaluate the safety and tolerability of apremilast when used in combination with TNF inhibition in patients with active RA.

To evaluate the clinical outcomes in RA using the individual domains of the ACR responder index1 .

To evaluate the clinical outcomes of RA using the Disease Activity Score (DAS28)2 To investigate the effects of apremilast on change in cytokine plasma concentration levels (from baseline to Week 12) and the achievement of an ACR response

Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Arthritis, Rheumatoid
  • Drug: Apremilast
    Apremilast 30mg BID
  • Drug: Placebo
    Placebo BID
  • Placebo Comparator: placebo
    Patient randomized to one of two arms, either placebo, or Apremilast
    Intervention: Drug: Placebo
  • Active Comparator: Apremilast
    Patients randomized to either placebo or apremilast
    Intervention: Drug: Apremilast
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2011
August 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Understand and voluntarily sign an informed consent form
  • 18 years of age at the time of signing the informed consent form.
  • Able to adhere to the study visit schedule and other protocol requirements
  • Must have a diagnosis of RA of at least 6 months duration based on the ACR criteria
  • Must have evidence of active disease with DAS-28 > 3.8
  • May be on one of the following DMARDs for at least 12 weeks and at a stable dose for at least 6 weeks:

    • Methotrexate 7.5-25mg/week
    • Hydroxychloroquine (200-400mg/day)
  • Must be on one of the following SQ TNF inhibitors at a stable, label approved dose for at least 12 weeks:

    • adalimumab (Humira®, Abbott Laboratories, North Chicago, IL)
    • certolizumab pegol (Cimzia®, UCB, Inc, Smyrna, GA)
    • golimumab (Simponi®, Johnson & Johnson, New Brunswick, NJ)
    • etanercept (Enbrel®, Amgen, Thousand Oaks, CA and Wyeth Pharmaceuticals, Philadelphia, PA)
  • Concommitant use of non-steroidal anti-inflammatory drugs and/or oral corticosteroids (prednisone<10mg/day or equivalent) are permitted if doses have been stable for at least 14 days.
  • If taking methotrexate, patient must also be taking folic or folinic acid at at dose of no less then 5mg/week.
  • Must meet the following laboratory criteria:

    • Hemoglobin > 9 g/dL
    • White blood cell (WBC) count; 3000 /;L (3.0 X 109/L) and 14,000/L (< 14 X 109/L)
    • Platelets; 100,000 /L (100 X 109/L)
    • Serum creatinine; 1.5 mg/dL (or 133mol/L)
    • Total bilirubin; 2.0 mg/dL
    • Aspartate transaminase (AST [serum glutamic oxaloacetic transaminase, SGOT]) and alanine transaminase (ALT [serum glutamate pyruvic transaminase, SGPT]); 1.5x upper limit of normal (ULN)
  • Females of childbearing potential (FCBP)‡ must have a negative urine pregnancy test at screening (Visit 1). In addition, sexually active FCBP must agree to use TWO of the following adequate forms of contraception while on study medication: oral, injectable, or implantable hormonal contraceptives; tubal ligation; intrauterine device; barrier contraceptive with spermicide; or vasectomized partner while on study. A FCBP must agree to have pregnancy tests every 4 weeks while on study medication and for one month after taking the last dose of study medication.
  • Males (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in reproductive sexual activity with FCBP while on study medication and for 28 days after taking the last dose of study medication

Exclusion Criteria:

  • Inability to provide voluntary consent
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  • Pregnant or breastfeeding
  • Systemic fungal infection
  • Active tuberculosis or a history of incompletely treated tuberculosis
  • History of recurrent bacterial infection (at least 3 major infections resulting in hospitalization and/or requiring intravenous antibiotic treatment within the past 2 years)
  • Clinically significant abnormality on the chest x-ray (CXR) with anteriorposterior and lateral views at screening. Chest x-rays performed within 3 months prior to start of study drug are acceptable.
  • Use of any investigational medication within 4 weeks prior to start of study drug or 5 pharmacokinetic/pharmacodynamic half-lives (whichever is longer)
  • Any clinically significant abnormality on 12-lead ECG at screening
  • History of congenital or acquired immunodeficiency (eg, Common Variable Immunodeficiency [CVID])
  • Hepatitis B surface antigen positive or Hepatitis B core antibody positive at screening
  • History of Human Immunodeficiency Virus (HIV) infection
  • Antibodies to Hepatitis C at screening
  • History of malignancy within 5 years prior to the screening visit (except for treated [i.e. cured] basal cell skin carcinomas and treated [i.e. cured] carcinoma in situ of the cervix)
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Mark Genovese, Stanford University
Stanford University
Celgene Corporation
Principal Investigator: Mark Genovese Stanford University
Stanford University
February 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP